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ABSTRACT
The suture is one of the most commonly used medical devices, consisting of a
fiber, a surgical needle and the packaging in which it is stored. The fiber itself remains
after implantation for a defined time and is responsible for the approximation of the
wound during the healing process. The needle merely serves to aid in insertion, and
preferably has a diameter larger than the diameter of the fiber .
The 1970’s marked the birth of a new family of fibrous materials for the
approximation of wounds: synthetic absorbable sutures. This family has the ability to
provide wound support during the early stages of wound healing, but also possesses the
ability to fully absorb over time. This reduces the incidence of complications that can be
caused by the permanent presence of a foreign body.
Currently, there are issues regarding the ability of the wound site to achieve
hemostasis, due to holes created by the needle that are not completely filled by the
suture. This blood leakage can lead to significant hemorrhaging and, in the case of
gastrointestinal surgeries, can lead to contamination and bacterial growth. The aim of
this research is to create a suture that is inserted with a diameter smaller than that of the
needle, but that increases in diameter after implantation to partially or fully fill this
hole. To achieve this end, a new amphiphilic suture line comprising polyethylene glycol
and a lactone monomer base (L-lactide, 1,4-dioxan-2-one) was investigated. This work
concluded with the selection of a quickly absorbing polymer composition that has
strength and long lasting strength retention comparable to commercially available
absorbable surgical sutures, but with the added ability to swell upon implantation. The
welling has the potential to aid in hemostasis at the wound site, reducing surgical
complications.
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INTRODUCTION
Early Usage of Fibers for Wound Closure
Physicians have been using fibers to approximate wounds for at least 4000 years.
Archaeological records show that linen, animal sinew, grass, cotton, animal gut, flax,
animal gut and silk were all used by the ancient Egyptians and East Indians to repair
wounds. As early as 131 AD, the Greek physician Claudius Galen described early forms
of the modern gut fiber used as sutures and, in approximately 300 AD, Greek surgeon
Antyllus used this material to perform bone and joint resections as well as tracheotomies
and repair of traumatic aneurysms. In the 1500’s, a French barber by the name of
Ambroise Paré, who eventually became a notable surgeon, used linen strips and silk for
vascular ligature repair [1]. In the 1800’s, buckskin and silverwire were first introduced.
In 1860, Joseph Lister, a British physician, developed gut sterilization techniques using
carbolic acid and, in 1880, he introduced a chromic acid salt-treated form of gut fiber that
actually had double the strength retention of plain gut suture. By the 1900’s, the German
biomedical industry was using sausage rapping materials derived from sheep intestines to
mass produce gut suture.
The Suture
The suture is one of the most commonly used medical devices and comprises a
fiber, a surgical needle, and the packaging in which the fiber and needle are stored. Upon
implantation, the fiber is the only part of this device that remains in place. As such, the
design of this fiber material is not just critical for the immediate approximation, but also
for the extended wound healing process. The needle is attached to aid insertion while the

packaging serves to preserve a dry, sterile environment for the suture prior to use [2]. In
order to address complications commonly associated with suture materials, as well as
improve the efficiency of the modern operating room, long overdue improvements to
modern suture design must be implemented.
In the 1900s, synthetic polymers began to become more prevalent; polyvinyl
alcohol was the first of these synthetic materials. However, with the advent of
polyglycolide in 1970, a new family of synthetic polymers arose that had the unique
ability to degrade by hydrolysis, as opposed to by attack by the body’s immune system.
Following this genesis, more polymers were developed using other cyclic ester
monomers as a base, sometimes augmenting these polymers with a carbonate monomer
known as trimethylene carbonate. These synthetic polymers comprise one or more of the
following monomers: glycolide (GLY), d-lactide, l-lactide (LLAC), 1,4 Dioxan-2-one
(PDO), trimethylene carbonate (TMC), ε-caprolactone, and vinyl alcohol [2]. Table 1
gives a chronological summary of the advent of these materials. [1]
Table 1. Chronological Arrival of Synthetic Suture Materials
Year Base Suture Material
1931 Polyvinyl Alcohol, “PVA”
1970 Polyglycolide, “PGA”
1974 Polyglycolide, “PGA”
1974 Poly(glycolide-co-l-lactide), “PGLA”
1981 Polydioxanone, “Poly-PDO”
1984 Poly(glycolide-co-trimethylene carbonate), “Polyglyconate”
1992 Poly(glycolide-co-ε-caprolactone) “Polyglecaprone”
1999 Poly(dioxinone-co-trimethylene carbonate-co-glycolide)
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Implantable Biomaterials
A biomaterial is any natural or synthetic substance that interacts with a biological
system. Accordingly, a biomaterial may be designed to facilitate medical treatment.
Typical biomaterials are metals, ceramics, glasses, or polymers. Polymers possess great
potential, due to their diverse range of physical and mechanical properties; these
biomaterials may be varied by modifying their composition, molecular weight, and
structure. Polymers can even be designed to degrade controllably to allow complete
absorption without further medical intervention.
In order to be suitable for use, absorbable materials must not invoke a sustained
inflammatory response, must maintain desirable properties long enough to serve their
function, must degrade into products that can be absorbed and ultimately excreted
without excessive toxicity, and must be processable to fit the desired application. Factors
that may affect these properties include chemistry, molecular weight, level of
hydrophilicity, surface charge, water intake, rate of degradation, and the toxicity of
erosion products resulting from the degradation of these degradable polymers.
Hydrolytically degradable polymers are of particular interest in wound closure.
These polymers can be broken down, independent of the body’s inflammatory/immune
response, by hydrolytic degradation of their chemical bonds.

Bonds susceptible to

hydrolysis include esters, anhydrides, carbonates, amides, phosphates, urethanes, and
acetals. Degradation rates and erosion mechanisms must be understood when using these
materials. Degradation rates vary between rapidly degrading phosphazenes and more
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hydrolytically stable polyamides.

Device geometry and water diffusion can also

dramatically affect that rate at which a degradable polymeric biomaterial can erode.
Degradation can either take place by surface erosion, bulk erosion, or a
combination of both.

Surface erosion takes place when the degradation and mass

absorption at the water-polymer interface exceeds the water diffusion into the device.
This leads to erosion primarily at the polymer surface. Bulk erosion occurs when water
diffuses into the material fast enough to cause uniform degradation throughout the
polymeric device [3]. This can however, lead to degradation of material toward the
center of the device, leading to a rapid release of degradation bi-products should the outer
shell breach.
Suture Materials
All suture materials fall into two categories: absorbable (ABS) or non-absorbable
(NA). Within these two categories are three types of materials: natural unmodified,
natural modified, and synthetic.
Nylon, polypropylene, silk, steel, and cotton are examples of NA sutures, while
ABS sutures comprise natural or synthetic materials. Most commercially available ABS
sutures lose at least 50% of their strength within 4 weeks; however recent technological
advances have resulted in lactide-based ABS sutures that can maintain a significant
amount of strength for up to 2 months. Strength retention typically comes with the
drawback that it takes months to years for many ABS sutures to fully absorb, since
strength loss is considerably faster than mass loss.
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Examples of modified natural sutures are plain gut and chromic gut, which are
both collagen-derived sutures. Plain gut and chromic gut were the first degradable
materials to be used and are still in use today. Gut sutures are primarily composed of
material derived from bovine intestinal serosa, but are also sometimes derived from the
submucosa of sheep or goat intestines. The primary material in gut suture is collagen but,
because it is animal based, it must be purified of antigenic elements such as proteins.
After processing the animal matter, this biomaterial is cut into ribbons and then treated
with formaldehyde, which increases its strength to more acceptable levels and slows the
degradation rate, leading to prolonged strength (having a load that is effective for
approximately 7 days for plain gut and 14 days for chromic gut) [4]. These ribbons are
twisted together and processed further to arrive at the final diameter. After the initial
processing, chromic gut is processed further by tanning in the presence of chromium
salts. Plain gut maintains usable strength for approximately 1 week and chromic gut
maintains its strength for approximately 2 weeks.

Despite the attempts to remove

antigenic matter, gut suture is known to have high tissue reactivity [5]. This material is
used on fewer occasions due to its short effective strength retention, low knot security,
high cost to produce, high tissue reactivity, and due to increased concern about
Creutzfield-Jacob Disease (Mad Cow Disease) [4].
Homopolymers of glycolide, 1,4 Dioxan-2-one, l-lactide, and ε-caprolactone
degrade/lose strength from fastest to slowest in the order as listed. These polymers are all
in the family of poly(α-esters) and possess hydrolysable aliphatic ester bonds in their
backbones. Polyglycolide is a strong/stiff polymer that, when fashioned into a suture, has
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good knot security and quick absorption characteristics.

This quick degradation,

however, means that it retains its strength for a shorter period of time while rapidly
releasing high levels of glycolic acid, which sometimes leads to an undesirable
inflammatory response.
The steric hindrance of the methyl group in polylactide slows the rate of
hydrolysis.

For example, a polylactide homopolymer would have a slower loss of

strength and a longer time of residence in vivo than a glycolide homopolymer, which is
similar in structure to lactide, but lacking the steric hindrance of the methyl group. This
slower degradation results in a slower release of degradation byproducts. Polylactide
suture material, however, can take over five years to be absorbed by the body. Like
polyglycolide, poly(l-lactide) is relatively stiff, has good strength, and has good knot
security [4].
Polydioxanone is a homopolymer of 1,4 dioxan-2-one and is softer than both
polylactide and polyglycolide.

PDO sutures generally have strength retention and

degradation profiles that are intermediate to those of polylactide and polyglycolide.
TMC and ε-caprolactone are mainly used as modifiers rather than as primary monomers
in homopolymers/copolymers and are usually only used to modify mechanical properties
of the other poly(α-esters) [2]. Indications, compositions, and absorption characteristics
of commercially available absorbable sutures implanted in humans are given in Table 2.
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Table 2. Suture Compositions, Indications, and Absorption/Strength Retention Properties
Breaking
Strength
Retention
SutureA
Composition
Indication
(BSR)/Maximu
m Time to Full
Resorption
7-10 Days %
Gut
Collagen
/<70 DaysB [6]
21-28 Days 0%
Chromic
Collagen
Gut
General soft tissue approximation /<90 Days B [6]
and/or ligation, but not for use in
5 Days 5%
PolyglytoneTM
cardiovascular
or
neurological
CaprosynTM
10 Days 25%
6211
tissues, microsurgery, or ophthalmic /< 56 Days [7]
surgery
75/25
7 Days 50-60%
ε14 Days 20-30%
MonocrylTM
Caprolactone
/91-119 Days[8]
/Glycolide
Soft tissue approximation and/or
2 Weeks 65%
ligation including use in ophthalmic
DexonTM
Glycolide
3 Weeks 35%
procedures, but not in cardiovascular
/ 60-90 Days[9]
or in neural tissue
All
types
of
soft
tissue
approximation, including use in
pediatric cardiovascular,
tissue
where growth is expected to occur,
and opthalmic surgery. PDS II
2 Weeks 70%
1,4
Dioxansuture
is
not
indicated
in
adult
4 Weeks 50%
PDS IITM
2-one
cardiovascular tissue, microsurgery
6 Weeks 25%
and neural tissue. These sutures are /< 6 Months[10]
particularly useful where the
combination of an absorbable suture
and extended wound support (up to
6 weeks) is desirable.
A

Gut and chromic gut are manufactured by Covidien and Ethicon. BSR values and resorption
times for gut sutures was provided by Ethicon. CaprosynTM and DexonTM are Covidien products.
MonocrylTM and PDS IITM are produced by Ethicon. BGut suture degradation is primarily due to
enzyme response, so BSR and absorption times vary by individual
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Suture Fabrication
Suture fabrication is accomplished either by melt extrusion, gel-spinning, or by
forming natural materials into fibers. A drawing process may follow extrusion, where the
fiber is heated and polymer chains are aligned to orient the amorphous regions and
crystalline regions axially, thereby increasing the strength of the fiber.

To create

multifilament sutures, small diameter fibers are combined by braiding and are then
stretched to tighten the construction of the suture, further increasing the strength of the
suture. Monofilament and multifilament sutures are often processed further by annealing
and relaxing the suture to increase the strength and dimensional stability of the suture.
The surface characteristics are then frequently modified by adding a coating to change
the frictional characteristics, decrease the reactivity with tissue, improve the knot quality,
or to control the release of a drug, such as an antimicrobial agent.
Geometrical Variations for Sutures
Suture type and size is chosen based on factors such as the surgical site as well as
the patient’s immune history, age, weight, health, and historical response to sutures.
Suture size is based on the diameter of the suture strand, which is defined by the United
States Pharmacopoeia (USP) [11].

Multifilament sutures are constructed of braided

filaments; typically, materials used in multifilament sutures have a relatively high
Young’s Modulus, making them less suitable for monofilament application; however,
despite the higher material stiffness, the ease of use, or “hand”, of multifilament sutures
is perceived to be much better, resulting in fewer throws being necessary for a secure
knot. Because of the braided nature of multifilament sutures, the suture strength is less
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susceptible to damage caused by handling. Unfortunately, braided sutures have distinctly
greater surface area than monofilament sutures, which makes braided sutures more
susceptible than monofilament sutures to bacterial colonization. Furthermore, the higher
surface area of multifilament sutures results in higher tissue friction, meaning that more
tissue trauma occurs upon entry into the wound area. For this reason, braided sutures are
usually coated.
Needles
In order to minimize drag, the needle diameter and its relationship to the diameter
of the fiber. To minimize drag, the needle diameter should be larger than the fiber to
which it is attached. Modern needles are typically swaged. Drilled swaging, used for
larger size needles, is accomplished by drilling a hole into the distal end of the needle and
using an adhesive to hold the suture in place. Recent advances in laser-drilled swaging
techniques have reduced the necessary needle wire diameter for a given size suture.
Mechanisms of Suture Absorption and the Wound Healing Process
Neutrophil proteolysis, an immune response is the primary degradation
mechanism for collagen-based sutures, inherently causing them to be more reactive than
other types of absorbable sutures. This reactivity can lead to scarring. Hydrolysis, or
degradation by water, is the primary degradation mechanism for synthetic sutures, which
causes them to be less reactive.
The three major stages of wound repair are inflammation, cell proliferation, and
remodeling. The initial response to a breach in the skin’s integrity is the appearance of
platelets, causing hemostasis through fibrin clot formation and also signaling
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macrophages and fibroblasts to migrate to the site of injury.

The recruitment of

neutrophils, lymphocytes, and macrophages marks the beginning of the inflammatory
process. The proliferative phase significantly overlaps the inflammatory phase, resulting
in the formation of the epithelium by cells migrating across a provisional matrix. The
proliferative phase also results in the formation of blood vessels, collagen deposition, and
formation of extracellular matrix. Remodeling of the collagen follows the proliferative
phase, as does regression and vascular maturation, with the entire phase lasting 6-24
months from the time of injury for humans [12].
The Inflammatory Phase and Scar Formation
The early inflammatory phase, which begins within minutes of injury, has a large
influence on the areas of scar formation. Migration of neutrophils and macrophages is
stimulated by growth factors and cytokines.

Metalloproteinases and collagenases,

released by neutrophils as well as macrophages, begin to break down tissue with free
radicals, resulting in a void that is ultimately filled with scar tissue. One study, using a
PU.1 null mouse, a type lacking macrophages and neutrophils, showed incisional and
excisional wound healing rates that were statistically not different from those of wild type
rats, but showing no scar formation. Cell death was even reduced, due to differences in
the cytokine and growth factor profiles for the PU.1 null mouse, coincident with the lack
of scar formation. Other studies centered around platelets and mast cells showed that
these mediators are not essential to effective wound repair. These studies suggest that
reducing the inflammatory response can reduce scar formation [12].
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Hydrophilicity
It has been shown that hydrophilic surfaces encourage greater cell attachment
than hydrophobic surfaces [13]. Surface wettability, a parameter that can be measured by
surface contact angle, reflects the distribution of surface-free energies on the implant
surface. Hydrophilic surfaces tend to have alternating surface polarities, as opposed to
hydrophobic surfaces, which behave neutrally. It has been further demonstrated in vitro
that surface-free energy and electric field have a marked ability to affect cell adhesion
and growth. This occurence is believed to be due to the binding of cationic amino acids
and proteins as well as inorganic cations to a more negatively charged implant, making
the implant more attractive to a cell membrane, which is negatively charged. In a study
conducted by Kloss and coworkers, titanium discs with coatings of varying hydrophilicity
were implanted under the subdermal soft tissue layer of the abdominal skin of 24 Wistar
rats. The rats were euthanized/evaluated after 1 and 4 weeks (12 rats per time-point).
The fibrous layer and soft tissue were stained and evaluated at each time-point, and it was
observed that the vascularization and cell number were significantly increased for the
tissue-implant interface with the more hydrophilic discs (i.e. the surface with the lower
contact angle).
The Cells Involved in Wound Healing
Wound healing is centered around a tissues’s own damaged or lost cells, which
are usually terminally differentiated.

In myocardial tissue, and other non-dividing

tissues, lost cells are never replaced, but in other tissues, such as continuously dividing
tissues, cells are constantly being lost and replaced throughout a lifetime.
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This

regenerative capacity lies in stem cells deep within the tissue. Stem cells are unique in
that they have the ability to self-renew and the capacity to differentiate into multiple cell
types.

The two types of self-renewal are symmetric replication and asymmetric

replication. In the former case, a stem cell differentiates into two daughter stem cells,
also self-renewable, while in the later case, one daughter cell remains self-renewing while
the other continues differentiating.
Embryonic stem cells, a type of pluripotent stem cells, can differentiate into any
type of cell. Adult (or somatic) stem cells are multipotent, so are limited to a narrower
range of differentiation pathways and, therefore, cells. Adult stem cells are found in most
tissues in the body, including the gastrointestinal epithelial lining, cornea, continuously
dividing tissue (e.g. skin), hematopoietic tissue, adipose tissue, liver, and pancreas.
Despite the longtime belief that cells in the central nervous system do not proliferate,
stem cells are sometimes even found there.
Stem cells typically reside in micro-environments within a tissue that are made up
of both stem cells and non-stem cells. The stem cells are stimulated by neighboring nonstem cells to divide when necessary. This signaling causes a stem cell to divide more
rapidly than it would on its own.
Other cells instrumental in wound healing include fibroblasts, macrophages, and
endothelial cells. Healing of wounded tissue to its original state is usually impossible;
hence, fibroblasts, driven by growth factors and cytokines, are necessary to replace the
region of lost cells with an acellular collagenous tissue. Macrophages, in addition to
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digesting foreign matter, release fibroblast-stimulating growth factors as well as
keratinocyates and endothelial precursors [14].
Hemostasis of Needle Hole Bleeding
In a study comparing the use of fibrin glue (FG) to thrombin-soaked gelatin
sponges as needle hole sealants, FG was shown to be more effective in achieving
hemostasis of needle hole bleeding, but risk of infection due to the use of these naturallyderived substances could not be ruled out [15]. In the case of gastrointestinal surgeries,
anastomoses can be contaminated, and FG promotes bacterial growth, leading to elevated
risk of infection. Therefore, a clinically relevant solution to this issue has not been found
to date [15].
Bioswellable sutures were designed to lessen the disparity between the suture
cross-section and that of the needle, in order to mitigate blood loss through the needle
hole, resulting in lower amounts of blood loss and a lower incidence of infection. This
approach is potentially useful to colorectal, cardiovascular, and laparoscopic surgery
[15].
In most cases, due to limitations in manufacturing processes, the needle diameter
far exceeds that of the suture it is guiding, manifesting in a needle-to-suture crosssectional ratio that can be as high as 2:1 or 3:1, resulting in blood leakage and increased
potential for infection [14]. A study was conducted by Miller and coworkers in 1987, in
which polypropylene sutures were used to augment a 6mm polytetrafluoroethylene
(PTFE) graft interposed in an end-to-end fashion in the infrarenal canine aorta (total of 82
canines). In this study, anastomotic bleeding was reduced from 33.4mL to 4.3mL per
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anastomosis when a suture:needle cross-sectional area ratio of 1.00:1.00 was used instead
of 1.94:1.00 (Total n=82). The conclusion of this study was that use of a needle-to-suture
ratio of 1:1 greatly reduced graft needle hole bleeding [15].
Scar Formation and Return to Function
Hematomas, which result from ongoing bleeding, create excessive extrudate and
are powerful stimuli in the formation of scarring. Infection is a condition that can cause
secondary inflammation, breaking up pre-existing scar tissue, leading to additional
collagen deposition, and ultimately leading to additional formation of scar tissue. The
synthesis-lysis mechanisms are balanced in a healthy adult, under ordinary conditions.
Injury-induced inflammation, however, causes a hormonal stimulation for the enzyme
collagenase, a pervasive enzyme typically found in rheumatoid synovial cells and postpartum uterine tissue. Collagenase activity is highest at the site of injury. Infection is a
condition that causes secondary inflammation, which in turn leads to the additional
resorption and synthesis of collagen, and ultimately additional scar formation. Therefore,
it is believed that conditions providing a reduction in hematoma formation and reduced
chance for infection will restore tissue to back to full function more quickly [16].
Sutures and Grafts
Peripheral vascular and colorectal anastomoses are complicated by the need for
graft suturing as well as direct suturing. Because of a risk of infection in the intestinal
area as well as a high potential for blood loss in vascular applications, monofilament
sutures are used for these purposes.

While only indicated for use in pediatric

cardiovascular applications, PDS II and Maxon, which both maintain at least 25% of their
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initial strength for up to 6 weeks, are among the few absorbable sutures approved for
cardiovascular use at all (Manufacturers “Instructions for Use”).
In one study, end-to-end anastomoses were performed in the iliac arteries of
growing pigs using both non-absorbable polypropylene (Prolene) suture and absorbable
polydioxanone (PDS) suture. PDS was shown to be superior to Prolene because of a
much lower inflammatory response, and a much lower blood loss through the needleholes (6.1±4.7 ml/min/100gm for PDS vs. 16.8±2.3 ml/min/100gm for Prolene). The
conclusion of the study was that PDS was clearly superior to Prolene for this application
[17]. Another swine study compared the newer PDS II to Prolene. The results of this
study showed full absorption of the PDS II, a lower inflammatory response to the PDS II,
and equivalent vascularization. It was noticed, though, that thrombus formation occurred
in one sample where PDS II was used, so the possibility of aneurysm formation must be
considered when using PDS II for an anastomosis [1].
In addition to minimizing blood leakage, a suture must maintain sufficient
strength for approximating a wounded tissue closure.

The wound closure is

accomplished within 10-14 days, but the remodeling phase for tissue can last several
months, so the suture must maintain sufficient strength for the risk of wound dehiscence
to pass.
Current suture methods for securing a graft during anastomoses are imperfect, due
to the needle hole which is left by a larger diameter needle; therefore, it is often necessary
to supplement these needle holes with a sealant to prevent blood loss and infection. One
method of preventing bleeding along the suture line is to apply a hemostatic aid such as
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oxidized cellulose, bovine collagen, and gelatin, which all provide a mechanical scaffold
on which autogenous thrombus will form. Another method is to apply topical thrombin
or a fibrin sealant, which involves mixing two separate solutions containing fibrinogen
and thombin, thereby forming a clot. Despite the ability of these agents to form clots, the
preferred graft material, PTFE, is itself resistant to adhesion with any substance, which is
problematic [2].
BioGlueTM Surgical Adhesive (CryoLife, Inc.) is a product containing
glutaraldehyde and bovine serum, which are mixed immediately upon application using a
static mixing device.

Albumin and amine groups within the tissue react with the

glutaraldehyde, resulting in rapid polymerization and reaching full strength in 2-3
minutes. While the ability of BioGlueTM to achieve hemostasis has its advantages,
BioGlueTM does create some safety concerns due to the damage it causes to exposed
nerves and cardiac conduction tissue, as well as due to its ability to leak into the
bloodstream through needle holes. In addition to its capacity for leaking through the
anastomoses, BioGlueTM is also problematic due to the potential of polymerized pieces to
undergo secondary mobilization and enter the blood stream. These particles, infamously
known as “BioGlueTM Bullets” present a serious stroke risk [3].
Cyanoacrylate adhesives are also used at the tissue-graft juncture, both as needlehole fillers and stand-alone fixation devices. Commercial cyanoacrylates, particularly Nbutyl-2-cyanoacrylate, act quickly to achieve hemostasis, especially in the treatment of
arteriovenous shunts and femoral bypass procedures. However, a study performed using
Sprague-Dawley rats demonstrated that when an anastomosis was sutured with
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polypropylene and no sealant, the burst strength was 168±58 mmHg, but when
Histoacryl® N-butyl-2-cyanoacrylate was added as a sealant, the burst strength dropped
to 60±38 mmHg. This is possibly due to tissue damage and subsequent tissue strength
loss that is caused by heat released by the exothermic reaction necessary for
cyanoacrylate to approximate. Additionally, there are toxicity concerns, and sealant entry
into the wound can impede healing.
Statement of Purpose and Research Plan
The ideal suture possesses high tensile strength, is easy to use, triggers a low
tissue reaction, and absorbs relatively quickly, while also providing adequate strength
retention for the task at hand. Also, a suture system with a needle diameter that is larger
than the suture and that is able to achieve quick hemostasis of needle-hole bleeding is
desired. Such a perfect suture system should have a high needle-to-suture ratio when
inserted, but have a low needle-to-suture ratio when healing is initially commencing.
It is believed that a swellable material can be achieved through implementation of
a family of polymers known as synthetically-derived polyethers. This family of water
soluble, highly biocompatible polymers has been used extensively in tissue and drug
delivery applications for over 30 years.

Polyethylene glycol (PEG) is a particular

polyether of interest due to its high ratio of water uptake ability to unit weight, while
copolymers of ethylene glycol and propylene glycol are also of interest because of their
intermediate levels of hydrophilicity.
The focus of this research is to implement these polyethers into poly(α-ester)
based chains to increase their hydrophilicity, which will allow them to swell, and in turn
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swell to fill the needle holes, to be inductive to cell in-growth, and to increasingly
encourage absorption with time through their ability to draw water closer. This thesis
describes attempts to form hydroswellable, load-supporting polymers that maintain their
strength for a commercially useful length of time.
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MATERIALS AND METHODS
Raw Materials
The primary components of all of the reactions involved in this study consist of
the α-ester family of monomers initiated by polyether diols.

Glycolide (G) and

trimethylene carbonate (TMC) were purchased from B.I. Chemicals. The ε-caprolactone
(CL) was purchased from Acros Organic. Polyethylene glycol (PEG) of two different
molecular weights, 20 and 35 kDa, were purchased from Sigma Aldrich. A random
copolymer with a molecular weight of 12 kDa, composed of 75 weight % ethylene glycol
and 25 weight % propylene glycol (PRP) was purchased from Sigma-Aldrich Chemicals,
l-Lactide (L) was purchased from Purac, 1,4 dioxan-2-one (PDO) was purchased from
Medichem, and tin (II) 2-ethylhexanoate (SnOct) was purchased from Alpha Aesar.
These materials are summarized in Table 3.
Table 3. Chemical Reagents
Chemical Name

Supplier

Polyethylene Glycol, Mn 20,000 g/mol
(PEG20K)
Polyethylene Glycol, Mn 35,000 g/mol
(PEG35K)
Trimethylene Carbonate (TMC)
1,4-Dioxan-2-one (PDO)
Glycolide (G)
L-Lactide (L)
Tin (II) 2-ethylhexanoate (SnOct)

Sigma
Aldrich
Sigma
Aldrich
BI Chemical
Medichem
BI Chemical
Purac
Alfa Aesar
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CAS #
(Unless Noted Otherwise)
25322-68-3
25322-68-3
2453-03-4
3041-16-5
502-97-6
4511-42-6
301-10-0

Equipment
All reactions were performed under positive nitrogen pressure in a 1L stainless
steel kettle/stirrer, equipped with a three-neck glass lid, a PTFE gasket at the interface of
the lid/kettle, a PTFE bearing/glass adapter, a penny-head stopper, and a 90° adapter with
a shut-off valve, shown in Figure 1. Prior to reaction, the initiator (PEG or PRP) was
dried in the kettle under vacuum with the PTFE bearing/glass adapter absent and replaced
with glass straight adaptors terminated with a 90° adapter/shut-off valve, in order to
completely seal the reaction setup and achieve an absolution pressure < 0.500 torr.

Figure 1. Reaction Equipment
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A vacuum pump (Welch Duoseal® Belt-Drive High Vacuum Pump or an
equivalent model) was used to apply vacuum. Heat to the kettle was supplied indirectly
by heated oil (Ace Glass High Temperature Silicone Bath Oil) in a steel reservoir. A
resistance heater, powered by a 1400W temperature controller, was used to heat the oil.
Positive nitrogen pressure was regulated using an Ace Glass Firestone® valve. The
vacuum line was routed through this valve as well, allowing simple alternation between
positive nitrogen pressure and vacuum.
Copolymer Synthesis
The polymeric initiators, PEG, were dried under vacuum (< 0.500 torr) at 110140°C. High molecular weight, fiber-forming, crystalline, amphiphilic copolymers were
prepared by end-grafting the polymeric initiator under positive nitrogen pressure with one
or more of the following cyclic monomers: l-lactide, glycolide, trimethylene carbonate, εcaprolactone, and PDO. Polymers were made using PEG with a molecular weight of
20,000 g/mol or 35,000 g/mol to evaluate the impact of molecular weight for polymers
with the same weight percent PEG.
Polymer Grinding and Monomer Removal
Following polymer synthesis, the polymers were cryogenically cooled with liquid
nitrogen to assist with particle size reduction. In this cooled state, an aluminum shaft was
struck with a hammer to remove the polymer from the reaction kettle. Once removed,
using a hammer and chisel, the polymer was broken into pieces approximately 1.5 inches
or smaller, immersing the polymer in liquid nitrogen as necessary to keep the polymer
brittle. The polymer was placed back into the liquid nitrogen to thermally equilibrate.
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These polymer pieces were fed into a Thomas Model 4 Wiley® Mill to mechanically mill
them into granules, assuring that the granules were less than 6mm in size, using a 6mm
sieve at the exit of the grinder. Upon exit from the grinder and the 6mm sieve, the
polymer was mechanically sieved to remove particles smaller than 1000 µm.
After sieving, the particles greater than 1000 µm were transferred to a 2000 mL
glass recovery flask, then heated under reduced pressure (<0.500 torr) at elevated
temperatures using a Buchi Rotovapor R-200 rotary evaporator to remove unreacted
constituents (also referred to as devolatilization, DV). A typical heating scheme for the
lactide-based polymers consisted of 40°C for 4 hours, 80°C for 2 hours, and 110°C for
3.5 hours. The collection flask was cooled with liquid nitrogen, thereby encouraging
condensation of vaporized monomer as well as maintaining a low vapor pressure within
the vacuum setup. Because of the lower melt typical for polydioxanone copolymers, it
was necessary to lower the maximum temperature for PDO-based polymers, resulting in
a typical heating scheme for those polymers of 40°C for 4 hours and 80°C for 6 hours. In
addition to the liquid nitrogen cooling of the collection flask, a coiled glass tube inside
the condensation chamber was circulated with ice water (~4°C) at a rate of approximately
0.5 gallons/minute, using a submersible pump to drive the flow.
Fiber Formation
Fiber was extruded using an Alex James and Associates custom made ¾” screw
melt extruder, with 4 heating zones, a 0.584 Zenith Metering Pump, and a 60 mil round
hole dye. Extrudate was cooled with ice water and collected on a spool. The fiber was
then drawn to final diameter using custom heated godets with two heating zones,
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orienting the polymer chains as well (approximately 75°C for the first zone and 85°C for
the second).

The fiber was then annealed at 60-70°C while loosely wound on an

aluminum rack placed in an oven.

This annealing process was to increase the

crystallinity/strength as well as relieve residual stresses.
Material for testing included sterilized and non-sterilized samples. Sterilized
samples were stored in foil pouches with a tyvec portion allowing gas transfer, and were
sterilized using ethylene oxide, then sealed in such a manner that the fiber was sealed on
all sides by foil.
General Polymer/Fiber Characterization
Thermal Properties
The thermal properties were evaluated using a Perkin Elmer DSC6 Digital
Scanning Calorimeter (DSC). Samples weighing 5-10mg were placed into aluminum test
pans on a microbalance, then the lid was placed onto the sample and crimped on using a
special crimping tool. The polymer was then heated in an inert gas (N2g) environment at
a rate of 20°C/min, measuring the energy input differences between the sample pan and
an identical but empty reference pan heated at the same temperature rate.

Melt

temperatures, heat of fusion, and glass transition temperatures were measured in this
manner.
Nuclear Magnetic Resonance (NMR)
A Jeol 300 ECX spectrophotometer was used to perform proton NMR (H`) on the
samples, dissolved at a 1 wt% concentration in either deuterium substituted chloroform
(CDCl3) or deuterium substituted hexafluro-2-propanol (HFIP-D2). From the resulting
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spectrum and knowledge of the types of molecules possibly present, the final
composition of the polymer was determined.

In addition, unreacted constituent

monomers were detected using this means.
Gel Permeation Chromatography
Molecular weight was determined by gel permeation chromatography (GPC)
using Waters Styragel® columns and a Waters 2414 refractive index detector, with
dichloromethane (DCM) as the mobile phase. GPC is a size exclusion technique that
separates a polymeric sample dissolved in a solvent according to molecular volume.
Using this molecular volume, the number average molecular weight (Mn), the weight
average molecular weight (Mw), and the polydispersity index (PDI) were determined. Mn
is largely determined by the monomer to initiator ratio of the polymer (M/I) and is
strongly affected by the presence of lower molecular weight chains, due to their higher
number given the same mass as chains of higher molecular weight. Mw is more strongly
affected by larger chains, and is more indicative of the rheological properties of the
polymers. The polydispersity index (PDI) is the ratio of the Mw to the Mn. For a polymer
of perfectly uniform molecular weight distribution, this ratio is 1.000, but is usually
higher.
Inherent Viscosity (IV)
The IV in a dilute solution was determined using a Cannon Fenske Routine UTube Viscometer (CFRC Series) immersed in a water bath maintained at a temperature of
25°C. A volume of 10mL of a pure solvent, either chloroform (CHCl3) or hexafluoro-2propanol (HFIP), was loaded into the viscometer and allowed to thermally equilibrate to
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the bath temperature for at least 7 minutes. Solvent retention time was measured using a
stopwatch. A 25mg sample was then dissolved in that same solvent at a concentration of
1mg/mL. The relationship of these two retention times was then used to determine the IV
of the polymer in that solvent.
Stress-Strain Fiber Mechanical Testing
The mechanical properties of the fiber were determined at room temperature
using a MiniBionix Universal Tester (MTS), Model 858, equipped with a 1 kN load cell.
Fiber samples were secured in grips that were initially 70mm apart and then strained at a
constant rate of 1 mm/s, following USP 31 standardized methods for testing fibers [4].
Using these methods, the stress at failure was determined for both knotted and unknotted
fibers to determine the untied (straight) ultimate tensile strength (UTS) as well as the
knotted ultimate tensile strength (Knotted UTS). A measurement of fiber stiffness, the
Young’s modulus, was also found. The Young’s modulus (modulus) is defined as the
stress-strain slope of the tensile curve from zero elongation to the point of yielding.
The UTS for a straight fiber reveals the maximum strength properties of the
material, but the knot UTS indicates how high a load the fiber can support when knotted
as it would be during use. An annotated stress-strain curve similar to that used in the
study is shown in Figure 2.
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Figure 2. MTS Fiber Tensile Testing Setup

In vivo and in vitro Breaking Strength Retention (BSR)
Percent in vitro breaking strength retention (BSR) was measured by testing the
ultimate tensile strength using the previously described method, before and after
incubation for predetermined time periods in a 7.4 pH phosphate buffer at known
temperatures.
In order to determine the percent in vivo BSR, sutures purified by devolatilization
were sterilized by ethylene oxide. Ethylene oxide sterilized sutures approximately 27 cm
in length were implanted above the legs of Spraque Dawley rats samples were tested
using the stress-strain method described above. Identical samples were subcutaneously
implanted in Sprague-Dawley rats for extended periods of time, then tested using the
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same stress-strain method described above.

The results were compared to the pre-

implantation results to determine in vivo BSR.

Figure 3. Rat Implant Sites for BSR

Assessment of Suture Swelling Properties
Each suture was cut into 6-inch pieces and secured in a loop fashion using a
clamp. This loop was submersed in 0.1M phosphate buffer with 0.2 wt. % Tween 20 as a
detergent, which was added to accelerate water uptake, allowing for fast comparative
results. The portion of the loop opposite the clamp was observed using a Leica optical
microscope before and after submersion for a controlled amount of time. The purpose of
the loop was to assure that the fiber was in same axial orientation before and after testing,
since the fibers were not completely cylindrical.
In vitro Absorption Assessment
Percent in vitro mass loss, a predictive measure for in vivo absorption rate, was
measured by weighing dry samples of the polymer before and after incubation for
predetermined time periods in a 7.4 pH phosphate buffer at known temperatures, with the
sample being rinsed and dried to a constant weight under reduced pressure after removal.
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In vivo Absorption Assessment
In order to evaluate and compare the absorption and tissue reaction of each suture
material, ethylene oxide sterilized (ETO) test suture materials were implanted
subcutaneously in the gluteal muscle of Sprague Dawley rats. This method was approved
by The Clemson University Institutional Animal Care and Use Committee (IACUC).
The rats were maintained by the Godley-Snell Research Center at Clemson University
for pre-determined lengths of time, at which point the rats were humanely euthanized
with carbon dioxide gas.

Following euthanization, the rats were perfused using

glutaraldehyde. The gluteal muscles were explanted and stored in 10% formalin, until
being sectioned and processed into microslides using hematoxylin and eosin staining.
Reactive changes were then assigned a severity score by a licensed
histopathologist (1=minimal, 2=mild, 3=moderate, and 4=severe), who evaluated an
scored observable tissue reaction.
Statistical Analysis
Statistical analysis was performed selectively on groups of particular interest in
this study to determine the significance of the data. Due to large differences in variance,
the particular method used was an independent two-samples t-test for unequal sample
sizes with unequal variance (Welch’s t-test). Sample standard deviations are combined,
if necessary by calculating the square root of the sum of squared standard deviations
being added. Standard deviations (s), sample number (n), and the sample average ഥ
X are
necessary for this calculation. The number of degrees of freedom (d.f.) and the t statistic
are calculated according to equations 1 and 2.
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Eq. 2

RESULTS AND DISCUSSION
Development of 1,4 Dioxan-2-one-Based Candidates for Fiber Formation
Polymer compositions for an initial group of l-lactide based polymers, initiated by
PEG 20,000 using an identical monomer:catalyst molar ratio (M/C), are summarized in
Table 4.
Table 4. Compositions for PEG20K-Initiated L-Lactide-Based Polymers
Lot
Polymer CompositionB
Information
Wt.% Wt.
Wt.
NameA Lot
Reagent
Reagents
PEG %
%
Lac/TMC
LAC1 1
8%
0% 92%
(96/4,mol)
1
Lac/Gly
LAC2
8%
0% 92%
(94/6,mol)
2
LAC3 1
9%
16% Lac/ε-Cap
75%
Lac/ε-Cap
LAC4 1
9%
9% (85/15,mol) 82%
(96/4,mol)
LAC5 1
23%
2% TMC
75%
A
All lots had an M/C = 3000 and were initiated by PEG 20,000 kg/mol
B
Lac=l-lactide, ε-Cap= ε-caprolactone, TMC=trimethylene carbonate,
Gly=glycolide

The molecular weight of the polymer was determined using GPC, with methylene
chloride as the solvent (DCM, CH2Cl2). In addition, the rheological behavior of the
polymer and the melt-extruded pre-fibrous form of this polymer were evaluated by
determining the inherent viscosity (IV), with methane trichloride as the solvent
(chloroform, CHCl3). These analyzed properties are given, along with the weight percent
l-lactide (% lactide) and weight percent PEG (% PEG) for each polymer in Table 5.
Tensile properties of the fibers, as determined using the MTS tensile testing machine, are
provided in Table 5, Table 6a, and Table 6b.
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Table 5. Polymer Properties for PEG20K-Initiated L-Lactide-Based
PolymersA (n=1 for DSC, GPC, I.V.)
Lot Information
Name and
Lot

LAC1

1

DSC Data

Mn
% PEG
Theory,
% Lac
kg/mol
8%
89%

250

8%
89%

167
42
152
24

1
LAC2

Tm,°C
Total ∆H,
J/g

250
172
29

2

LAC3

1

9%
76%

222

174
47

LAC4

1

9%
81%

222

177
48

GPC Data

DV
Ext.
I.V.
I.V.
(µDV), (µEXT),
PDI
dL/g
dL/g

MW
Def.

MW

Mn
Mw
Mp
Mn
Mw
Mp
Mn
Mw
Mp
Mn
Mw
Mp

131
1,135 8.7
296
245
1,443 5.9
300
168
596
3.6
210
98
1,856 19.0
148
No Data

2.05

1.13

2.01

1.10

2.07

1.58

1.49

0.94

1.91

-

69
Mn
LAC5 1
87
Mw 1,030 14.9 0.97
94
Mp
A
MW = molecular weight, MW Def . = molecular weight definition, Mn = number
average MW, Mw = weighted average MW, Mp = peak value MW, PDI = polydispersity
index (ratio of Mw to Mn), DV I.V. = Inherent Viscosity of Devolatilized Polymer, Ext.
B
I.V. = Inherent Viscosity of Extruded Polymer
Diam. = fiber diameter, M =
Young’s modulus, % Elong = strain at failure
23%
73%

156
35
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Table 6a. Fiber Properties for PEG20K-Initiated L-Lactide-Based FibersA (n=5)
Strength, MPa
Mod.,
% Elong
Name and Diam., mm
UTS
Knot UTS
Lot
Avg±Std
Avg±Std
Avg±Std
Avg±Std
Avg±Std
LAC1 1 0.37 ± 0.0 4.3 ± 0.3 54 ± 7.6 379 ± 39 255 ± 20
0.60 ± 0.0 3.3 ± 0.1 67 ± 5.3 365 ± 21 221 ± 19
1
0.39 ± 0.0 4.5 ± 0.1 47 ± 3.5 483 ± 48 310 ± 32
LAC2
0.38 ± 0.0 4.3 ± 0.4 43 ± 8.3 345 ± 37 276 ± 21
2
0.24 ± 0.0 4.4 ± 0.4 45 ± 1.9 365 ± 18 255 ± 18
LAC3 1 0.10 ± 0.0 3.0 ± 0.5 93 ± 7.7 372 ± 5 359 ± 5
LAC4 1 0.37 ± 0.0 2.7 ± 0.2 59 ± 1.6 317 ± 2 241 ± 2
LAC5 1 0.25 ± 0.0 2.3 ± 0.1 87 ± 5.9 221 ± 2 214 ± 1
A
Diam.=Diameter, Mod.=Modulus, %Elong=%Elongation,
Avg=Average, Std=Standard Deviation
Table 6b. Sample Means and Standard Deviations for Modulus and UTS
Mean Modulus ±
Mean UTS ± Standard
Name
Standard Deviation (n)
Deviation (n)
LAC1
4.3±0.3 (n=5)
379±39 MPa (n=5)
A
LAC2
3.3±0.58 (n=20)
390±67 MPa (n=20)
LAC3
4.5±0.5 (n=5)
372±5 MPa (n=5)
LAC4
4.3±0.2 (n=5)
317±2 MPa (n=5)
LAC5
4.4±0.1 (n=5)
221±2 MPa (n=5)

Swellable polymers, as discussed in this study, are a system of polymers that is
unique due to the presence of both a hydrophilic component and a hydrophobic
component (amphiphilic). The hydrophilic component comprised either polyethylene
glycol with a molecular weight of 20,000 g/mol (PEG 20K) or polyethylene glycol with a
molecular weight of 35,000 g/mol (PEG 35K). The hydrophobic component consisted of
l-lactide, glycolide, TMC, or ε-caprolactone. The effects of fiber composition on fiber
properties was investigated. Correlations of relationships affecting these properties are
plotted in Figures 4a-3d and Figures 5a-5b.
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Figure 4a. Effects of PEG on Strength

Figure 4c.
Modulus

Figure 4b. Effects of Lactide on Strength

Effects of PEG on Young’s Figure 4d. Effects of Lactide on Young’s
Modulus

Figures 4a-4d. Tensile Effects of Wt. % PEG 20K (%PEG) and Wt. % l-lactide
(%Lactide)
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Figure 5a. Ability of Mn, Mw, and Mp
(GPC) to Predict Strength

Figure 5b. Ability of Inherent Viscosity to
Predict Fiber Strength

Figures 5a-5b. Correlation of Molecular Weight Definitions and IV to Predict UTS

As demonstrated in Figure 3a, % PEG is more useful in predicting the expected
UTS of the fiber, with a better correlation coefficient (R2) of 0.75. It is less useful in
predicting the Knot UTS, with the best R2 value available using fitted equations only
being 0.21. Figure 3b shows that %Lactide has a lower correlation than % PEG for UTS
and knot UTS. Neither one shows a strong correlation. PEG and % Lactide showed
equal potential to predict Young’s Modulus with an R2 values of 0.52 (Figures 3d and 3f).
The best predictors of UTS were actually those requiring the least operator
attention to detail and the least time-on-task, namely, the GPC measurements Mn and Mp
(R2=0.81 and 0.75 respectively). Contrary to previous beliefs, as demonstrated in Figure
4b, the IV for the melt extruded polymer was not useful in predicting UTS (R2=0.08).
The IV for the devolatilized polymer was a better predictor (R2=0.66).
As expected based on the %PEG and %Lactide, the highest average UTS values
were observed for LAC1 and LAC2, polymers with average values that are very close.
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The calculated values for d.f. and the t-value are calculated using equations 1 and 2
(d.f. =10.84 and t-value = -1.232).

A 2-tailed Welch’s t-test was performed, with the

null hypothesis being that the strengths are equal. The resulting P value is 0.25, which is
much greater than 0.05, therefore the null cannot rejected. Therefore, based on this
calculation, LAC1 and LAC2 may have the same strength.
While high UTS and knot UTS values are desirable, it is preferred that the
Young’s modulus be lower to improve the “hand” of the fiber (an industry term
describing the ease of handling and knot characteristics of a suture). LAC3 and LAC4
both show potential based on their % PEG content and apparent high fiber strengths,
coupled with lower moduli. LAC5, while expected to uptake the largest amount of water
(and therefore swell the most) has an expectedly low UTS and knot UTS.
Polymer synthesized with the higher molecular weight initiator was expected to
allow an Mn that was higher for a given %PEG than that of PEG20K. The compositions
for these polymers are given in Table 7. The corresponding properties of these polymers
are given in Tables 8a, 8b, and 8c.
Table 7. Compositions for PEG35K-Initiated Polymers
Lot Information Polymer Composition
Name and
Wt.% Wt.
Wt.
Reagent
Reagents
A
Lot
PEG %
%
1
TMC/εLac/ε-Cap
LAC6
15% 10% Cap
75%
(96/4,mol)
2
(97/3,mol)
1
TMC/εLac/ε-Cap
LAC7 2
20% 10% Cap
70%
(96/4,mol)
(97/3,mol)
3
TMC/εLac/ε-Cap
LAC8 1
25% 10% Cap
65% (96/4,mol)
(97/3,mol)
A
All lots had an M/C = 3000 and were initiated by PEG 20,000 kg/mol
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Table 8a. Polymer and Fiber Properties for PEG35K-Initiated
Polymers/FibersA (n=1 for DSC, GPC, I.V.)
DSC Data GPC DataA
Lot Information
Name and
Lot

% PEG
% Lac

Mn
Theory,
kg/mol

1
LAC6

2

15%
73%

233

3

DV
I.V.
(µ ),
dL/g

Tm,°C
Total ∆H,
J/g

MW
Def.

MW

176
36

Mn
Mp

141
200

1.60

157
38

Mn
Mp

104
148

1.68

159
32

Mn
Mp

76
148

1.65

DV

160
Mn
95
1.28
28
Mp
144
20%
85
161
Mn
175
LAC7
3
1.26
68%
33
Mp
151
160
Mn
136
5
1.25
28
Mp
91
79
25%
152
Mn
LAC8
1
140
1.13
63%
35
Mp
103
A
MW = molecular weight, MW Def . = molecular weight definition, Mn =
number average MW, Mw = weighted average MW, Mp = peak value MW, DV
I.V. = Inherent Viscosity of Devolatilized Polymer
1

Table 8b. Polymer and Fiber Properties for PEG35K-Initiated Polymers/Fibers (n=5)
Strength, MPa
Diam., mm
Mod.,
% Elong
Name and
UTS
Knot UTS
Lot
Avg±Std
Avg±Std
Avg±Std
Avg±Std
Avg±Std
0.22 ± 0.00 3.3 ± 0.1 58 ± 5.3 409 ± 26 293 ± 7
1
0.31 ± 0.00 3.2 ± 0.1 60 ± 2.7 427 ± 9 274 ± 23
LAC6
2 0.40 ± 0.03 3.3 ± 0.4 57 ± 3.1 389 ± 68 261 ± 12
0.33 ± 0.02 2.9 ± 0.3 64 ± 5.5 406 ± 23 269 ± 28
3
0.37 ± 0.01 3.3 ± 0.1 57 ± 2.6 488 ± 32 267 ± 28
1 0.28 ± 0.00 1.8 ± 0.1 99 ± 8.5 312 ± 7 288 ± 6
LAC7
3 0.38 ± 0.02 2.5 ± 0.2 81 ± 5.5 296 ± 21 259 ± 21
5 0.47 ± 0.02 2.6 ± 0.2 69 ± 9.1 270 ± 23 232 ± 12
15
± 9.7 214 ± 8 213 ± 25
LAC8
1 0.24 ± 0.01 0.9 ± 0.0
7
A
Diam.=Diameter, Mod.=Modulus, %Elong=%Elongation, Avg=Average, Std=Standard
Deviation
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Table 8c. Sample Means and Standard Deviations for Modulus and UTS
Polymer Mean Modulus ±
Mean UTS ± Standard Mean Knot UTS ±
Name
Standard Deviation (n) Deviation (n)
Standard Deviation (n)
273±48 (n=25)
LAC6
3.2±0.53 (n=25)
424±83 (n=25)
LAC7
2.3±0.30 (n=15)
168±32 (n=15)
260±25 (n=15)
LAC8
0.9±0.03 (n=5)
214±8 (n=5)
213±25 (n=5)

The resultant fiber properties of the fibers composed of LAC6, LAC7, and LAC8
are comparable to those of LAC1-LAC5, and allow the utilization of PEG content that is
at least 6% higher than that of any of the previously specified PEG20K-initiated
polymers of acceptable strength. LAC8 has strength that is lower than desired. LAC6
has the highest UTS of the three polymers, but the Knot UTS for this fiber is nearly
equivalent to the proven repeatable knot UTS of LAC7. This can be demonstrated with a
two tailed Welch’s t-test analysis of LAC6 vs. LAC7, which results in a p-values of
0.075. Therefore, with alpha set to 0.05, there is not necessarily a difference between the
knot strengths for LAC6 and LAC7. A t-test on LAC7 vs. LAC8, however, demonstrates
that there is a very low p-value between these two polymers (p-value=0.002). Therefore,
it can be determined that there is a difference in knot strength between these two
polymers.
In order to make a final determination about the relative suitabilities of LAC6 and
7 as swellable fiber candidates, the in vitro BSR, the swelling capability, and the mass
loss data is compared in Tables 9-11.
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Table 9. Break Strength Retention for LAC6 and LAC7 (n=4)
Break Strength Retention (BSR)
Lot Information
Fiber Tensile DataA
% BSR±S by Week (n=4)
Initial
Name and
Diam., mm
UTS, MPa
1
2
3
Lot
(n=4)
(n=4)
0.31±0.00
427±9
82±3.7
78±1.0
71±4.5
1
0.22±0.00
409±26
80±2.9
75±1.1
72±1.6
0.13±0.00
487±12
87±10.2
82±0.8
76±1.6
2
0.19±0.01
455±47
78±9.0
74±1.2
LAC6
0.31±0.00
406±50
78±5.6
0.36±0.02
324±35
72±1.0
3
0.48±0.00
296±27
79±1.3
416±87
81.0±15.4 76.7±2.6 73.0±5.0.
Average for Group ± ST (nT)
(nT =7)
(nT=20)
(nT=24)
(nT =12)
Lot Information
Break Strength Retention (BSR)
Fiber Tensile DataA
% BSR±S by Week (n=4)
Name and
UTS, MPa
1
2
3
Lot
Diam., mm
(n=4)
(n=5)
(n=5)
(n=2)
0.28±0.00
312±7
69±20.1
57±2.3
50±0.5
1
0.22±0.01
299±30
70±17.8
57±0.5
79±4.5
LAC7
2
0.34±0.01
351±23
65.1±5.4
0.38±0.02
296±21
85±5.1
68±2.7
3
0.43±0.00
303±9
62±2.9
52±1.3
312±192
73.0±27.8 59.8±6.6 50.0±0.5
Average for Group ± ST (nT)
(nT=20)
(nT=4)
(n=20)
(nT=20)
A
Diam. = fiber diameter, N/A = Not Applicable
Table 10. Simulated Physiological Condition Swelling in vitro
(0.1M/7.4 pH/37°C Phosphate Buffer)
Name
% PEG
PEG MW
Diameter, mm ∆CA in 1 HrA
LAC6
PEG35K
0.13
15
10.5±1.1%
LAC6
PEG35K
0.19
15
6.9±1.0%
LAC6
PEG35K
0.22
15
1.8±3.3%
LAC6
PEG35K
0.36
15
5.5±0.3%
LAC7
20
PEG35K
0.28
13.5 ± 1.6%
LAC7
20
PEG35K
0.29
4.6 ± 0.3%
LAC7
20
PEG35K
0.29
6.41±3.10%
LAC7
20
PEG35K
0.38
6.05 ± 0.92
LAC8
25
PEG35K
0.28
65.7 ± 1.0%
A
∆CA=change in cross-sectional area
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Table 11. Simulated Physiological Condition Mass Loss in vitro (0.1M/7.4 pH/37°C
Phosphate Buffer)
LAC7 - 7.4 pH/37°C
LAC6 - 7.4 pH/37°C
Time
4 Month
12 Month
15 Month

% Mass Loss (n=3)
0.13 A
0.33 A
7.5±0.6
7.4±1.2
58.3±1.9 37.1±1.4
64.8±5.7 52.3±6.4

Time
4 Month
6 Month
12 Month
15 Month

% Mass Loss (n=3)
0.18
0.28
0.43
15.2±0.2 18.8±1.2 13.0±0.8
25.5±1.9 21.4±0.7
67.9±9.7 83.0±5.9 51.5±4.6
55.8±3.7
-

While the BSR for LAC6 is longer than the BSR for LAC7, the swelling
capability is less than that of LAC7. Also, given the increased time period necessary to
fully absorb LAC6, of the l-lactide-based fibers evaluated, LAC7 appears to be the best
candidate for a long-lasting fiber.
Assessment of 1,4 Dioxan-2-one-Based Fibers
In order to investigate an alternate polymer system to the l-lactide-based polymer
system, a separate polymer system based on 1,4-Dioxan-2-one (PDO) was investigated.
This polymer system was expected to have a BSR profile more closely aligned with full
absorption and is also closer in composition to PDS-II, a commercially available
monofilament suture in prevalent use.

This family of PDO-based polymers was

catalyzed with an M/C equal to 5000 and initiated by either polyethylene glycol with a
molecular weight of 14,000 g/mol (PEG14K) or PEG20K and is summarized in Table 12.
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Table 12. Compositions for PEG-Initiated PDO-Based Polymers
Polymer Composition
Wt.%
PEG
Wt.
Wt.
NameA
Reagents
Reagent
PEG
MW
%
%
Gly/PDO
PDO1 8
20K
1
91% PDO
(50/50,mol)
Gly/PDO
PDO2 6
20K
1
93% PDO
(50/50,mol)
Gly/PDO
PDO3 4
20K
1
95% PDO
(50/50,mol)
Gly/PDO
PDO4 6
14K
1
93% PDO
(50/50,mol)
A
All lots had an M/C = 3000 and were initiated by PEG 20,000 kg/mol

GPC was not possible, due to the polymer family insolubility in methylene
chloride (DCM), so molecular weight properties of the polymer and the melt-extruded
pre-fibrous form of these polymers were evaluated by determining the inherent viscosity
(I.V.), with hexafluoro-2-propanol (HFIP) as the solvent. Tensile properties of the fibers
were determined with MTS. These analyzed properties are given, along with the weight
percent PDO (%PDO) and weight percent PEG (% PEG) for each polymer in Tables 13a
and 13b.
Tensile properties of the PDO fibers, as determined using the MTS tensile testing
machine, are given in Tables 13a and 13b. The knotted and unknotted strengths of the
fibers were determined in a fashion identical to that used for the lactide based polymers.
In addition, the Young’s modulus and the amount of strain realized before failure of the
suture was also determined. The stress-strain curve is nearly identical in shape to that of
the l-lactide based polymers. The corresponding properties for these polymers are given
in Tables 13a and 13b .
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Table 13a. Polymer and Fiber Properties for PEG20K-Initiated PDOBased Polymers/Fibers
Lot Information
Name

PDO1

Lot #

1

DSC Data
% PEG
% PDO

8%
91%

Mn
Tm,°C
(Theory),
Total ∆H, J/g
kg/mol
101
59

250

109
74
101
70
102
58
104
69

3
1
2
PDO2

3

6%
93%

333

105
67

4
PDO3 1
PDO4 1

4%
95%
6%
93%

105
71
104
73

500
233
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DV
I.V.,
dL/g

2.08
2.58
2.70
3.16
2.47
2.27
3.58
2.15

Table 13b. Polymer and Fiber Properties for PEG20K-Initiated PDO-Based
Polymers/FibersA (n=5)
Strength, MPa
Name
Diam., mm
Mod.,
% Elong
and
UTS
Knot UTS
Lot
Avg±Std
Avg±Std
Avg±Std
Avg±Std
Avg±Std
0.20 ± 0.00 2.2 ± 0.2 46 ± 3.2
510 ± 38
426 ± 32
1 0.30 ± 0.02 1.3 ± 0.2 54 ± 5.7
432 ± 40
290 ± 27
PDO
0.46 ± 0.02 0.7 ± 0.1 69 ± 3.9
339 ± 32
231 ± 23
1
0.21 ± 0.00 1.3 ± 0.1 51 ± 2.2
485 ± 27
349 ± 29
3
0.25 ± 0.01 2.3 ± 0.1 45 ± 2.4
592 ± 20
462 ± 34
1 0.33 ± 0.01 1.1 ± 0.0 54 ± 1.5
472 ± 19
216 ± 21
2 0.10 ± 0.01 1.5 ± 0.2 67 ± 12
834 ± 85
560 ± 46
0.32 ± 0.01 1.5 ± 0.1 44 ± 3
451 ± 37
NA
PDO 3
0.54 ± 0.05 1.0 ± 0.1 51 ± 3.3
358 ± 51
206 ± 17
2
0.11 ± 0.01 0.6 ± 0.2 171 ± 63.3 298 ± 63
325 ± 50
4 0.21 ± 0.01 0.7 ± 0.0 63 ± 9.5
440 ± 32
296 ± 26
0.34 ± 0.01 1.1 ± 0.1 58 ± 10.4 476 ± 27
253 ± 15
PDO
1 0.37 ± 0.01 0.8 ± 0.0 97 ± 5.7
±
±
296
23
291
12
3
0.19 ± 0.01 2.3 ± 0.2 49 ± 5.1
621 ± 34
372 ± 31
PDO
1
4
0.34 ± 0.01 2.3 ± 0.1 46 ± 4.7
640 ± 37
385 ± 19
A
Diam.=Diameter, Mod.=Modulus, %Elong=%Elongation, Avg=Average, Std=Standard
Deviation, NA = Not Available

The PDO DV increased with increased design molecular weight; however, the
resulting strength of the fiber was not affected in a predictable manner. This result is
somewhat counterintuitive. Weight percentage of PEG and weight percentage of PDO
had no effect on strength either. Crystallinity only slightly decreased as the weight
percentage of PEG increased (as the weight percentage of PDO decreases), but it should
be noted that the weight percentage of PEG was only varied between 4-8%. These
observations are shown in Figures 6a-6c.
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Figure 6a. Effects of PEG on Strength

Figure 6b. Effects of Design
MW on Strength

Figure 6c. Effects of PEG on Crystallinity (∆H)
Figures 6a-6c. Tensile Effects of Wt. % PEG (%PEG) and Polymer MW (Theoretical)
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Table 14. Break Strength Retention for PDO1-4
Break Strength Retention (BSR)
Lot
Fiber Tensile Data
Information
%BSR by Week / Final UTS, MPa
(n=4)
Initial
Name and Diam., mm
UTS,
2
3
4
6
Lot
(n=4)
MPa
(n=4)
0.30±0.02 62.6±5.8 76.2±12.2 68.8±16.0
1
0.46±0.02 49.2±4.6 79.7±2.7 75.0±2.4
0.492±0.02 37.2±3.8 92.1±10.0 83.7±15.7
PDO1
3

0.24±0.00

94.0±0.3

61.9±0.16

-

34.8±1.9

-

Average for Group ± ST 60.8±8.3 74.4±16.3 75.8±22.5 34.8±1.9
(n=16)
(n=16)
(n=12)
(n=4)
(nT)
0.33±0.00 51.9±7.4 35.6±2.4
16.2±9.8 12.2±9.0
1
0.30±0.01 74.5±1.7 46.8±23.5
39.1±4.4 26.9±1.2
0.54±0.05 80.8±2.6 84.0±3.7
41.6±15.3 17.5±14.0
PDO2 3
0.32±0.01 65.4±5.4 86.0±4.2
27.6±9.5 15.7±0.7
0.21±0.01 63.8±4.7 68.7±10.1
65.0±8.0 21.2±11.2
4
0.34±0.09 54.8±3.9 88.0±1.0
51.0±13.6 38.1±3.2
40.1±26.2 18.7±20.4
Average for Group ± ST 65.2±11.4 68.2±26.3
(n=24)
(n=24)
(n=24)
(n=24)
(nT)
PDO3 1
0.37±0.01 43.0±3.3 73.9±2.7
60.5±1.8 43.6±2.4
60.5±1.8 43.6±2.4
Average for Group ± ST 43.0±3.3 73.9±2.7
(n=4)
(n=4)
(n=4)
(n=4)
(nT)
0.19±0.01 90.0±4.9 64.4±11.6
35.9±12.7 14.0±5.1
PDO4 1
0.34±0.00 79.9±3.9 83.5±1.5
59.6±8.4 24.6±12.8
85.0±6.3
74.0±11.7
47.8±15.2
19.3±13.8
Average for Group ± ST
(n=4)
(n=4)
(n=4)
(n=4)
(nT)
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Table 15. Simulated Physiological Condition Swelling in vitro
(0.1M/7.4 pH/37°C Phosphate Buffer)
Name % PEG PEG
Diam,
∆CAA
PDO4 6
PEG14K 0.19
8.4 ± 1.8
PDO4 6
PEG20K 0.34
9.5 ± 1.4
PDO2 6
PEG20K 0.11
11.0
±
PDO2 6
PEG20K 0.21
6.9 ± 1.34
PDO2 6
PEG20K 0.32
5.8 ± 2.31
PDO2 6
PEG20K 0.33
8.1 ± 2.2
PDO2 6
PEG20K 0.36
7.1 ± 1.80
PDO2 6
PEG20K 0.43
5.3 ± 1.58
PDO2 6
PEG20K 0.54/
5.7 ± 1.46
A
% Change in Cross-Sectional Area
Table 16. Simulated Physiological Condition Mass Loss in vitro
(0.1M/7.4 pH/37°C Phosphate Buffer)
Time-point
% Mass Loss by
Diameter
PDO2
PDO4
0.29mm
0.34mm
1.4 Month (6 Week)
22.3 ± 1.4 5.4 ± 0.4
1.8 Month (8 Week)
34.1 ± 1.6 7.3 ± 0.1
4.0 Month (17.4 Week)
73.1 ± 5.7 5.1 Month (22 Week)
84.6 ± 1.8

While the % BSR for PDO2 and PDO4 do not appear to be different, the average
initial strength of PDO4 22N higher. This suggests, therefore, that the PDO4 fiber was
stronger at the same time-point. Additionally, given limited data, it appears that the
cross-sectional area changes in vitro for PDO4 were at least as high as those for PDO2. It
actually appears that for this system of fibers, fiber strength decreased with increased
theoretical molecular weight and that PDO4 actually had comparable strength to that of
PDS-II®.
Additionally, the in vitro mass loss rates for both fibers are very comparable to
those of PDS-II, as presented in the product packaging. Despite the shortcomings of
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PDO2 relative to PDO4, PDO2 was tested more extensively because it was perceived to
be the better candidate at the time.
Assessment of Primary Candidates for a Swellable Fiber
LAC7, PDO2, and PDO4 were all chosen as potential candidate polymers for
processing into absorbable, swellable sutures due to their favorable properties relative to
the other polymers with similar compositions. Low modulus, high strength (particularly
knot strength), and an ability to maintain strength for a longer timeframe are all desirable
properties, while a low rate of mass loss is undesirable.
Fiber properties can change during ethylene oxide sterilization. When sterilizing
absorbable, synthetic polymers, it is common for the moduli to decrease, thereby
improving the hand of a fiber, but also decreasing the strength.

In addition, the

elongation often increases. The simultaneous occurrence of increased elongation and
decreased modulus allows the material to maintain more of its toughness, an engineering
definition corresponding to the amount of energy a material can absorb without fracture.
The fiber properties before and after sterilization are shown in Table 16. This
table also shows the percent changes for the modulus, elongation, and strengths. LAC7
and PDO2 fibers with corresponding diameters are shaded in gray. The average values
for several of the parameters listed in Table 17 are given in Table 18, in order to
quantitatively compare these properties.
Parameters used to assess polymer behavior under various conditions, but which
are not important to the final mechanical properties are percent change in modulus,
percent change in elongation, and percent change in strength. It is noticed that EtO
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treatment of PDO2 tended to increase modulus, while EtO-treated LAC7 became softer.
Percent elongation at failure increased, for both fibers, with EtO treatment, but 14% more
for EtO-treated LAC7. The average strength, both knot UTS and UTS, decreased for both
fiber types with EtO treatment. This result is likely due to presence of moisture in the
sterilization process at elevated temperature. It is believed that PEG content of the
polymers is conducive to water absorption, and therefore decreased the molecular weight
by chain cleavage during sterilization.
Sterilized PDO4 has a higher UTS, higher Knot UTS, and lower Modulus than
sterilized LAC7, which can be seen in Table 16. The modulus was drastically lowered by
sterilization, presumably due to relaxation of the fiber. This decrease is likely due to
greater mobility in the chains as well as the lower glass transition temperature of PDO. It
should be noted that the single lot of PDO that was sterilized had tensile properties that
were the most favorable of all, but insufficient data exists to evaluate a trend.
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PDO4

PDO2

LAC7

Name

Table 17. Fiber Properties Before and After SterilizationA
Fiber Tensile Properties
Modulus (M), % Elongation (E), Strength (S) and
Changes of These Properties (∆) Due to the
Diameter.,
Ethylene Oxide Sterilization Technique Used
Status
mm
S, MPa
∆S, %
M,
∆E,
∆M E, %
Knot
Knot
MPa
%
UTS
UTS
UTS
UTS
Before
0.18
3.3
69
469 338
-9%
3%
-10% -11%
After
0.19
3.0
71
427 303
Before

0.21

2.1

After

0.22

2.2

Before

0.28

1.8

After

0.3

1.8

Before

0.29

2.4

After

0.31

2.1

Before

0.33

2.7

After

0.39

2.2

Before

0.44

2.5

After

0.46

2.3

Before

0.21

0.7

After

0.21

0.7

Before

0.24

0.9

After

0.24

0.9

Before

0.28

1.1

After

0.28

1.3

Before

0.32

1.5

After

0.33

1.5

Before

0.43

1.1

After

0.42

1.2

Before

0.34

0.9

7%
0%
-11%
-16%
-6%
8%
0%
22%
-1%
2%
-15%

85
109
99
118
83
95
82
102
81
94
63
62
156
186
137
147
44
46
58
65
67.1

28%
19%
15%
24%
16%
-2%
19%
8%
4%
13%

317

296

269

310

283

241

228

393

283

331

262

262

-

207

-

303

248

296

221

441

352

414

303

214

207

200

179

248

228

248

207
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317

372

241

476

324

434

283

647

374

-6%

-15%

-23%

-18%

-17%

-6%

-20%

-

-3%

-11%

-5%

-15%

-6%

-14%

0%

-8%

-17%

-25%

-8%

-15%

-9%
-4%
After
0.35
0.8
64.8
592 361
A
Shaded lines for LAC7 and PDO2 represent fibers with fibers of the other polymer of
corresponding diameters of 0.22, 0.29, 0.30, and 0.45, referenced in the Table 17.
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-3%

317

PDO2

LAC7

Name

Table 18. Changes in Fiber Properties Before and After Sterilization
Averaged Fiber Tensile Properties
Modulus (M), % Elongation (E), Strength (S) and
Changes of These Properties (∆) due to the
Diam.,
Ethylene-Oxide Sterilization Technique Used
mm
S, ksi
∆S, %
M,
∆M
E, %
∆E, %
Knot
Knot
ksi
UTS
UTS
UTS
UTS
0.21
2.2
7%
109
28%
296
269
-6%
-15%
0.28

1.8

0%

118

19%

241

228

-23%

-18%

0.29

2.1

-11%

95

15%

331

262

-17%

-6%

0.44
Average
±SDA
0.21

2.3
2.1
±0.2
2.2

-6%
-2.5
±7.8%
8.0%

94
104.0
±11.6
62

16%
19.5
±5.9%
-2%

296
291.0
±37.2
414

221
245.0
±24.0
303

-3%
-12.3
±9.4%
-5%

-11%
-12.5
±5.2%
-15%

0.28

1.8

22.0%

147

8%

248

207

0%

-8%

0.32

2.1

-1.0%
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4%

372

241

-17%

-25%

0.43
Average
±SDA

2.3
2.1
±0.2

2.0%
7.8
±10.2%

65
80.0
±45.4

13%
5.8
±6.3%

434
367.0
±83.4

283
258.5
±43.0

-8%
-7.5
±7.1%

-15%
-15.8
±7.0%

Table 19 compares the in vitro and in vivo BSR values for sterilized fibers. It is
apparent from the data that the in vitro methods used for predicting BSR produce data
that is very similar to the data produced by implantation in rats. In vivo conditions cause
quicker strength loss than in vitro, likely due to enzymatic influences in the body that are
not present in the buffer. PDO4, which starts out with the highest of initial strengths of
the three candidate sutures, also maintains strength the longest. In fact, the in vivo BSR
for the tested lot of PDO4 is actually greater than that of PDSII ® in vitro.

49

PDSII®

PDO4

PDO2

LAC7

Name

Table 19. Break Strength Retention of Fibers in vitro (ivt) & in vivo (ivv)
(n=6 for ivv, n=4 for ivt)A
Fiber
Initial
% BSR / (UTS, MPa)
EnvironDiam.,
UTS, ksi
4 Wk.
6 Wk.
ment
2 Wk.
mm
0.33±0.02 35.1±2.4
Ivt
74 ± 4.7 48 ± 1.8 25 ± 1.5
B
0.39±0.03 30.4±1.7
Ivv
55 ± 6.0 42 ± 5.1 30 ± 3.8
0.38±0.02 42.9±3.1
Ivt
47 ± 2.7 35 ± 0.7 24 ± 1.1
C
0.38±0.01 46.9±2.4
Ivv
42 ± 2.5 30 ± 4.0 20 ± 4.1
0.44±0.02 44.0±2.7
Ivt
86 ± 1.6 28 ± 1.2 16 ± 2.4
D
0.46±0.03 42.5±4.1
Ivv
47 ± 2.7 30 ± 1.4 19 ± 1.0
0.32±0.01 65.4±5.4
Ivt
89 ± 6.1 62 ± 11.4 28 ± 1.0
0.33±0.02 54.2±4.5
IvvE
70 ± 2.0 51 ± 5.0
0.42±0.01 63.2±2.4
Ivt
93 ± 23. 80 ± 4.4 51. ± 1.2
0.42±0.01 63.2±2.4
IvvF
49 ± 11. 31 ± 6.3 26 ± 3.0
0.34±0.00 79.9±3.9
Ivt
55 ± 4.7 42 ± 8.8 30 ± 13.
0.35±0.00

85.9±4.7

IvvG

68

± 6.4

53

± 8.4

0.33±0.01

80.5±2.1

ivv

93

±

80

±

44

± 2.4

A

Diam.=Fiber Diameter, Wk. = Weeks, BRat #’s 725/727/726 for 2/4/6 Week
Respectively, CRat #’s 687/691/692 for 2/4/6 Week Respectively, DRat #’s
683/684/685 for 2/4/6 Week Respectively, ERat #’s 681/684/682 for 2/4/6 Week
Respectively, FRat #’s Not Available, GRat #’s 702/703/704 for 2/4/6 Week
Respectively

After implanting sutures in Sprague Dawley Rats for up to 9 months, an American
College of Veterinary Pathologists Board-certified pathologist with experience in
determining the irritation potential of biomaterials examined these explanted samples
without any knowledge of the structural of chemical composition of the sutures, rating
each specimen for indicators of reactive changes on a scale of 1-4 (1 = minimal, 2 = mild,
3 = moderate, and 4 = severe). The specific indicators assessed were polymorphonuclear
neutrophils (PMNs), macrophages, lymphocytes, giant cells, fibrosis, and necrosis.
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Table 20 summarizes the histological findings for microscopic histological
samples derived from sutures implanted intramuscularly in the gluteal muscles of
Sprague Dawley rats. The sum of the individual pathology severity scores for each
suture was indicative of the overall biocompatibility of that suture when implanted
intramuscularly. Figures 7, 8, and 9 show explanted histological samples used for these
determinations. PDO2 showed a high level of reactivity after 3 months, but this was very
likely due to very rapid degradation occurring at this time, resulting in no suture being
present after only 4 months. LAC7, on the other hand, was still present in considerable
amounts after at least 9 months. PDSII fully absorbed after at least 6 months.
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3

1

6

A

2

1

1

1
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754 L
6 Months

756 L

757 L

4 Months

1 Week

No suture present

9 Months

0
0
0
0
2
0

A

3-0

0.36 PDSII® Z317

-

0

0
3
1
0
2
0

1

0
0
0
0
1
0

0

754 R

0.38 LAC7 Lot 1

0.36 PDSII® Z317

0.38 LAC7 Lot 1
2-0
757 R

0.43 PDO2 Lot 1

0
2
0
0
1
0

1
2
1
0
2
0

1

1

0.43 PDO2 Lot 1

0.22 LAC7 Lot 1
3-0

755 L

Combined Score

0.36 PDSII® Z317

671 L

Suture/Muscle
Interface

PMN’s
Macrophages
Lymphocytes
Giant Cells
Fibrosis
Necrosis

0

0
1
1
0
1
0

Time of Implant
Months

3 Months

Rat NumberB

761 R

USP Suture Diameter
(For Synthetic Absorbable Suture)

3-0
2-0

Diameter (mm)A

668 L
721 L

Specimen

0.22 LAC7 Lot 1
0.32 PDO2 Lot 1

Table 20. Histological Rankings for Sutures Implanted in the Gluteal Muscle of Sprague
Dawley Rats

PDO2 1 Week

LAC7 1 Week

(Initial Diameter = 0.32 mm)

(Initial Diameter = 0.22 mm)

Monocryl 1 Week

(Initial Diameter = 0.37 mm)
Figure 7. One-Week Tissue Samples under Microscope
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PDO2 3 Month

LAC7 4 Month

(Initial Diameter = 0.43 mm)
(Initial Diameter = 0.38 mm)
Figure 8. Three and Four-Month Tissue Samples under Microscope

PDSII 6 Months

LAC7 6 Months

6 Month (Initial Diameter = 0.21 mm)
6 Month (Initial Diameter = 0.21 mm)
LAC7 9 Months

9 Month (Initial Diameter = 0.21 mm)
Figure 9. Six and Nine-Month Tissue Samples under Microscope
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CONCLUSIONS
Lactide/PEG-based hydroswellable polymers initiated by polyethylene glycol
(less than or equal to 35,000 g/mol) are not good candidates for swellable sutures because
the addition of enough polyethylene glycol to more than a 10% change in cross-section
results in unacceptable strength decreases. In addition, even after 9 months in vivo,
LAC7 was did not appear to degrade at a rate fast enough to allow full absorption in less
than a year.
The PDO-based polymers tested in this study are the better candidates for further
optimization because of their strength and their ability to absorb quickly relative to the
lactide based polymers .
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RECOMMENDATIONS
Efforts to improve the PDO system polymers may be quite successful, given the
single lot strength and BSR similarity of PDO 4 to that of PDSII, coupled with its proven
ability to swell in an aqueous environment while also absorbing completely in a
simulated physiologic environment within 4 months. A method for determining swelling
in vivo should be explored.
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